Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing, because that familiar routine of meetings, deadlines, and the like has, of course, returned. And this is a particularly busy start, given that two Woodstock-like events are underway for cancer researchers and biotech types. So grab a cup of stimulation as you peruse your agenda and brace for a dizzying array of data and conversation. Meanwhile, here are some tidbits to help you along. Hope you have a productive day and, as always, do keep in touch …
Insurers and their pharmacy benefit managers tout mail-order pharmacies as convenient alternatives, but in the world of expensive cancer drugs, the companies use their clout to force patients away from hospital- or clinic-based pharmacies and into their own mail-order operations, The Columbus Dispatch writes. Why? With many cancer drugs carrying the biggest price tags, rebates from drug makers, and profit margins, the benefit managers want to keep that money for themselves. But cancer patients are experiencing potentially harmful delays.
About the Author Reprints
In re the colon cancer drug pricing item, mayhaps it ‘feels like a longer time’ for those paying double? Mayhaps not …